Benzinga · Aug 7, 2026
Guggenheim Maintains Buy on GH Research, Raises Price Target to $40
Guggenheim analyst Eddie Hickman maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $34 to $40.
GH
NASDAQ · GHRS
GH Research PLC
Healthcare · Biotechnology
$28.19
Up+$1.15 (+4.08%)
Updated Aug 14, 2026, 3:43 PM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 857.25M
- P/E ratio
- -20.9
- Dividend yield
- 0.00%
- 52-week range
- $12.77 – $31.44
- Volume
- 352.26K
- Avg. volume
- 321.53K
Price performance
GHRS price history
1M range · 0 trading sessions · Daily adjusted prices
GHRS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest GHRS news
The latest Smart Investors Daily articles mentioning GHRS.
Stock researchCompany · Overview
GHRS research
Overview
Company profile and research snapshot.
Company profile
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $27.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Guggenheim | Buy | — |
| Aug 7, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 6, 2026 | Needham | Buy | — |
| Jul 27, 2026 | Wells Fargo | Overweight | — |
| May 19, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $40
Cantor Fitzgerald analyst Charles Duncan maintains GH Research (NASDAQ:GHRS) with a Overweight and raises the price target from $35 to $40.
Benzinga · Aug 6, 2026
Needham Maintains Buy on GH Research, Raises Price Target to $39
Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $32 to $39.
Benzinga · Aug 6, 2026
GH Research Q2 EPS $(0.23) Beats $(0.30) Estimate
GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 53.33 percent decrease over losses of $(0.15) per share from the
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
